Sudarshan Pharma Industries Limited is a vertically integrated pharmaceutical and specialty chemicals company operating across R&D, intermediates, APIs, finished formulations and branded generics, with contract manufacturing, trading subsidiaries and an export-focused footprint spanning Asia, the Middle East, Africa and select Western markets.

Financial momentum is notable: FY25 revenue reached INR 505.0 crore with EBITDA rising 75% to INR 39.9 crore and PAT improving to INR 16.0 crore, reflecting margin expansion driven by increased manufacturing sales, export ramp-up and mix improvement in resale of APIs and intermediates.

Strategic expansion is evident through acquisitions (Ratna Lifesciences, Ishwari Healthcare), new subsidiaries in Singapore and Dubai, development of local Vitamin B1/B6 manufacturing, and a proposed USD 35 million FCCB — all indicating Sudarshan Pharma Industries Limited is mobilizing capital and assets to scale exports and reduce China dependency.

Working capital intensity rose materially in FY25 with inventories at ~INR 140 crore, trade receivables ~INR 160 crore and short-term borrowings increasing to ~INR 160 crore, which alongside a higher debt-to-equity of 1.4x highlights Sudarshan Pharma Industries Limited's leverage and the need for disciplined cash conversion management.

Market credibility is supported by a blue‑chip client list including Cipla, Dr. Reddy's, Biocon and others, and by regulatory-ready documentation (IP/BP/USP standards), positioning Sudarshan Pharma Industries Limited as a China+1 supply alternative for specialty chemicals, intermediates and selected APIs.